13D Filings
ACELYRIN, Inc.
Initial Filing
Ownership

5.40%

Total Shares

5,393,846

Issuer CIK

1962918

CUSIP

00445A100

Event Date

Mar 5, 2025

Accepted

Mar 6, 2025, 11:55 AM

Reporting Persons (1)
NameType% of ClassAggregateSole VotingShared Voting
Trium Capital LLP
Investment Adviser
5.40%5,393,8465,393,8460
Disclosure Items (7)

Security Title

Common stock

Issuer Name

ACELYRIN, Inc.

Issuer Address

4149 LIBERTY CANYON RD., AGOURA HILLS, CA, 91301

Filing Persons

This statement is filed by Trium Capital LLP, a United Kingdom Limited Liability Partnership (the "Reporting Person"). The Reporting Person is an investment manager which holds the Shares of the Issuer in various private funds and accounts under its management.

Business Address

The business address of the Reporting Person is: 60 Gresham Street, London, EC2V 7BB, United Kingdom.

Principal Occupation

The principal business of the Reporting Person is to provide Investment Management for private funds and accounts under its management.

Convictions

None

Citizenship

The Reporting Person is incorporated in the United Kingdom.

The 5,393,846 shares reported herein by the Reported Person, were acquired at an approximate aggregate value of $12,075,934.95 of investment funds in accounts under management.

The Reporting Person purchased the shares of Common Stock for investment purposes. On Feb 6 2025, the Issuer, Alumis Inc., a Delaware corporation ("Alumis"), and Arrow Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Alumis ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Alumis and the surviving corporation of the merger (the "Merger"). The Reporting Person plans to engage and have discussions with the Issuer's management and Board relating to the Merger, the Issuer's business, operations, strategy, governance and related matters. Except as set forth herein or such as would occur upon completion of any of the actions discussed herein, the Reporting Person has no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D. The Reporting Person intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Board, price levels of the Common Stock, other investment opportunities available to the Reporting Person, conditions in the securities market and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, purchasing additional shares of Common Stock and/or other securities of the Issuer (collectively, "Securities"), disposing of any or all of their Securities, in the open market or otherwise, at any time and from time to time, and engaging in any hedging or similar transactions with respect to the Securities. The Reporting Person reserves the right to change their intention with respect to any and all matters referred to in this Item 4 of this Schedule 13D.

Percentage of Class

The aggregate number is 5,393,846. The percentage of the class of securities identified is 5.36%.

Number of Shares

5,393,846

Transactions

A summary table is included below of all transactions in the previous 60 days that the reporting person made in the issuer on behalf of a number of private funds and managed accounts under its management: Trade Date Notional Quantity ISIN CUSIP Average Price 10/02/2025 1.0000 SLRN US Equity US00445A1007 USD1.9200 11/02/2025 340,834.0000 SLRN US Equity US00445A1007 USD1.9846 12/02/2025 114,999.0000 SLRN US Equity US00445A1007 USD2.0000 13/02/2025 2,100,067.0000 SLRN US Equity US00445A1007 USD2.0296 14/02/2025 245,397.0000 SLRN US Equity US00445A1007 USD2.0981 18/02/2025 179,232.0000 SLRN US Equity US00445A1007 USD2.1419 19/02/2025 55,860.0000 SLRN US Equity US00445A1007 USD2.1261 20/02/2025 517,669.0000 SLRN US Equity US00445A1007 USD2.3169 21/02/2025 839,078.0000 SLRN US Equity US00445A1007 USD2.4655 24/02/2025 1,000,709.0000 SLRN US Equity US00445A1007 USD2.6197

Shareholders

N/A

Date of 5% Ownership

N/A

N/A

N/A

ACELYRIN, Inc. — Schedule 13D | 13D Filings